HILE(SH:603718) Xin Lang Cai Jing·2025-11-21 01:34Group 1 - On November 20, Haili Biological experienced a trading volume of 34.61 million yuan, with a financing buy amount of 4.85 million yuan and a net financing buy of 756,600 yuan [1] - As of November 20, the total balance of margin trading for Haili Biological was 208 million yuan, with a financing balance of 207 million yuan, accounting for 4.64% of the circulating market value, indicating a low level compared to the past year [1] - Haili Biological's main business involves the research, production, and sales of animal vaccines, with revenue composition being 71.34% from oral vaccines and 28.61% from IVD [1] Group 2 - As of September 30, Haili Biological had 33,800 shareholders, an increase of 7.16% from the previous period, while the average circulating shares per person decreased by 6.68% to 19,196 shares [2] - For the period from January to September 2025, Haili Biological reported an operating income of 150 million yuan, a year-on-year decrease of 14.15%, while the net profit attributable to the parent company was 20.33 million yuan, reflecting a year-on-year increase of 0.77% [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [2]